Janne Lehtiö
Professor in Medical Proteomics at Karolinska Institutet, Scientific Director, Science for Life Laboratory, Sweden and Head of Clinical Proteomics Unit, Karolinska Univ. Hospital
Data-Driven Precision Medicine and Diagnostics
Precision medicine is an approach for developing clinical decision support and improving healthcare by utilising molecular information (genomic, transcriptomic, proteomic, metabolomic, etc.), phenotypic and health data from patients to generate care insights with the goal of preventing or treating human disease which will result in improved health outcomes. By definition, precision medicine is based on complex data and data integration. In Sweden, the SciLifeLab & Wallenberg National Program for Data-Driven Life Science (DDLS) is set up to focus on data-driven precision medicine, among other themes, to make use of opportunities for advances in data science in the intersection of healthcare. Karolinska Institutet at Stockholm hosts the DDLS national precision medicine node.
Precision medicine research is expected to contribute with strong capabilities in machine learning, AI and other computational tools to make use of existing strong assets in Sweden, such as molecular data (e.g. omics), imaging, electronic health care records, longitudinal patient and population registries, biobanks and digital monitoring data. Will the precision medicine paradigm profoundly change healthcare in the near future and what are the hurdles in this complex changing landscape for improved personal health?
Bio
Janne Lehtiö has MSc degree from Helsinki University, Finland and PhD in engineering at Royal Institute of Technology (KTH) in Stockholm, Sweden. Post the PhD, Lehtiö worked a few years in biotech industry in USA and Europe; and obtained his postdoctoral experience in cancer research at Karolinska Institutet, Stockholm, Sweden. In 2015, he was selected to faculty Professor position at Karolinska Institutet and since 2021 holds shared clinical professor position at Karolinska univ. hospital heading cancer proteomics unit. Lehtiö is pointed as visiting professors at InFlames flagship program on immunology at University of Turku, Finland.
Lehtiö-labs major research focus in on proteome analysis, systems biology and cancer precision medicine. He’s lab is working from methods development to clinical applications mainly focusing on lung and breast cancer as well as in leukaemia research.
Lehtiö has also vast experience on research infrastructures, from heading core facilities and national infrastructure initiatives to expert assignments in the field of technology driven personalized medicine. Since 2018 Lehtiö serves, part time, as Scientific Director for SciLifeLab, Sweden’s national bioscience infrastructure and is engaged in SciLifeLab-KAW Data Driven Life Science program as steering group member and precision medicine area-lead. He also serves in Karolinska Comprehensive Cancer Center board of directors and scientific advisory boards for national infrastructures in both Finland (Biocenter Finland) and Norway (NAPI). Lehtiö is member of Nobel Assembly at Karolinska Institutet.
